Chief resident in the Psychiatry Residency Training Program at the University of Arkansas for Medical Sciences in Little Rock.
Vice chair for education and the associate program director of the Geriatric Psychiatry Fellowship at the University of Arkansas for Medical Sciences in Little Rock.
AMA J Ethics. 2023 Oct 1;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Alzheimer's disease (AD) is an incurable, progressive deterioration that ends, eventually, in death. For many years, AD's hallmark etiological feature was beta-amyloid plaque accumulation in the brain, but, to date, costly drugs designed to reduce beta-amyloid levels offer only marginal clinical benefit and pose significant risk of harm. Thus, there is strong interest in finding alternative AD-modifying interventions, and, despite controversy, aducanumab-an antibody-recently received approval by the US Food and Drug Administration. This article considers how ethical issues in the care of patients with AD could influence, for better or worse, clinicians' judgment about whether and when to recommend aducanumab.
阿尔茨海默病（AD）是一种无法治愈的进行性恶化，最终会导致死亡。多年来，AD 的标志性病因特征是大脑中β-淀粉样斑块的积累，但迄今为止，旨在降低β-淀粉样蛋白水平的昂贵药物仅提供了微不足道的临床益处，并带来了重大的伤害风险。因此，人们强烈关注寻找替代 AD 修饰干预措施，尽管存在争议，但 aducanumab-一种抗体-最近获得了美国食品和药物管理局的批准。本文考虑了 AD 患者护理中的伦理问题如何影响（无论是好是坏）临床医生判断是否以及何时推荐 aducanumab。
